Plain-English translation of NCT05408845 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing two different ways to treat advanced salivary gland cancers that have a protein marker called HER2. You would receive either (a newer targeted drug) or a combination of chemotherapy plus (the current standard treatment). The goal is to see which approach helps people live longer without their cancer growing.
Salivary gland cancers with HER2 are rare and hard to treat, and doctors don't yet know if the newer targeted medication works better than standard chemotherapy for these patients. This trial will help answer that question.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of two drug treatments every 3 weeks. Depending on which arm you join, you'll either receive the newer targeted medication or standard chemotherapy plus another drug. You'll have regular CT or MRI scans to check how your cancer is responding, blood tests, and possibly a biopsy. The study may last several months to over a year, and you can switch to the other treatment if your cancer starts growing again.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States